AbbVie outlines 2026 adjusted EPS of $13.95-$13.99 while raising expected revenue to $67.8B
AbbVie outlines 2026 adjusted EPS of $13.95-$13.99 while raising expected revenue to $67.8B(摘要待生成)
AbbVie Non-GAAP EPS of $3.82 beats by $0.05, revenue of $17.4B beats by $50M, raises FY guidance
AbbVie Non-GAAP EPS of $3.82 beats by $0.05, revenue of $17.4B beats by $50M, raises FY guidance(摘要待生成)
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress - Zacks Investment Research
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress - Zacks Investment Research(摘要待生成)
ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View - Zacks Investment Research
ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View - Zacks Investment Research(摘要待生成)
Is AbbVie a Buy After Its Latest Earnings Report?
AbbVie reported third-quarter revenue of $17.4 billion, up 10.3% year over year. [[fact:fact-4g73h93fn]] Adjusted EPS was $3.82, about $0.07 above the midpoint of management's guidance. [[fact:fact-2a9oqr3ez]] Skyrizi revenue rose 22.7% to $5.78 billion, while Rinvoq sales increased 23.9% to $2.71 billion. [[fact:fact-as9cjftcd]] Humira revenue fell to $683 million from $993 million a year earlier. [[fact:fact-dmqkmf8fl]] AbbVie announced a 5.2% dividend increase, raising its quarterly payout from $1.73 to $1.82 per share beginning in February. [[fact:fact-e2vryzzzg]]
Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)? - Yahoo Finance
AbbVie reported third-quarter 2026 sales of US$17.4 billion. [[fact:fact-606a43ruh]] The company reported third-quarter net income of US$4.2 billion. [[fact:fact-8zaos9x5p]] It raised full-year revenue and adjusted EPS guidance. [[fact:fact-z0j7jk6py]] AbbVie approved a 5.2% quarterly dividend increase to US$1.82 per share, starting with the February 16, 2027 payment. [[fact:fact-cw5rec2fi]] Analyst models project annual revenue growth of 8.2% over the next three years, but this projection is unconfirmed. [[fact:fact-njgaqyq4v]]
AbbVie (ABBV) Q3 2026 Earnings Call Transcript
AbbVie (ABBV) Q3 2026 Earnings Call Transcript(摘要待生成)
AbbVie earnings beat by $0.08, revenue topped estimates
AbbVie earnings beat by $0.08, revenue topped estimates(摘要待生成)
AbbVie reports improved facial satisfaction among weight-loss drug users
AbbVie reports improved facial satisfaction among weight-loss drug users(摘要待生成)
AbbVie raises dividend by 5.2% to $1.82
AbbVie raises dividend by 5.2% to $1.82(摘要待生成)
ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell? - Zacks Investment Research
ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell? - Zacks Investment Research(摘要待生成)
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? - Yahoo Finance
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? - Yahoo Finance(摘要待生成)
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie reported FY 2025 revenue of about $61.2 billion, up roughly 8.6% year over year. [[fact:fact-4gvtj6rto]] Bristol Myers Squibb reported FY 2025 revenue of about $48.2 billion, down 0.2% year over year. [[fact:fact-95u3rgr2o]] Skyrizi and Rinvoq together accounted for roughly 42% of AbbVie's total net revenue in 2025. [[fact:fact-hoa1rnq6p]] The article forecasts Bristol Myers Squibb's current fiscal-year revenue to rise 3% to $49.9 billion, but this projection is unconfirmed. [[fact:fact-pagal02qc]] It also forecasts Bristol Myers Squibb's net income to rise more than 40% to $11.2 billion, another unconfirmed projection. [[fact:fact-vqlcrohbl]] Bristol Myers Squibb faces a revived $6.7 billion lawsuit related to its Celgene acquisition. [[fact:fact-byyh3ckyl]]
Abbvie's Nxera deal, Nooks $500m, and the birth of Onvaro
Abbvie's Nxera deal, Nooks $500m, and the birth of Onvaro(摘要待生成)
AbbVie expands Oxford R&D facility as part of £120 million-plus investment
AbbVie expands Oxford R&D facility as part of £120 million-plus investment(摘要待生成)
AbbVie Reports Third-Quarter 2026 Financial Results
AbbVie Reports Third-Quarter 2026 Financial Results(摘要待生成)